|
25 May 2023 |
Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases
|
|
25 May 2023 |
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
|
|
25 May 2023 |
STADA: FDA approves biologics facility to supply RETACRIT® to patients in US
|
|
24 May 2023 |
Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology
|
|
24 May 2023 |
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
|
|
24 May 2023 |
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
|
|
24 May 2023 |
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
|
|
24 May 2023 |
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
|
24 May 2023 |
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
|
|
24 May 2023 |
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
|
|
24 May 2023 |
Cumberland Pharmaceuticals announces FDA clearance of IND for new treatment of idiopathic pulmonary fibrosis
|
|
24 May 2023 |
Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study
|
|
24 May 2023 |
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
|
|
24 May 2023 |
TrialSpark Announces First Patient Dosed in Phase 2 Clinical Trial for ASN008-201 in Atopic Dermatitis
|
|
24 May 2023 |
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
|
|
24 May 2023 |
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
|
|
24 May 2023 |
ReNAgade Therapeutics Launches with over $300 Million in Series A Financing To Unlock the Limitless Potential of RNA Medicine
|
|
24 May 2023 |
Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor
|
|
24 May 2023 |
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
|
|
23 May 2023 |
Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference
|
